STOCK TITAN

Olink Holding AB (publ) American Depositary Shares - OLK STOCK NEWS

Welcome to our dedicated page for Olink Holding AB (publ) American Depositary Shares news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding AB (publ) American Depositary Shares stock.

Olink Holding AB (publ) (Nasdaq: OLK) is a pioneering company in the field of proteomics, dedicated to accelerating scientific discoveries through its innovative Proximity Extension Assay (PEA) technology. Since its founding in 2016, Olink has been at the forefront of proteomics research, providing products and services designed to enhance the understanding of real-time human biology across multiple disease areas. The company’s platform is utilized by major biopharmaceutical firms, clinical institutions, and academic researchers globally.

Olink’s proprietary PEA technology is a versatile tool that enables researchers to conduct studies spanning from initial discovery to clinical trials and even diagnostic applications. This technology leverages existing lab infrastructure and installed instrumentation, making it a highly efficient and scalable solution.

Olink operates through two main segments: Kit and Services. In the Kit segment, the company provides reagents and consumables that researchers can use in their own laboratories. The Services segment offers access to Olink’s technology through its own labs, delivering high-quality data and insights to clients worldwide.

The company is headquartered in Uppsala, Sweden, and has a significant presence in Europe, North America, and Asia. Key revenue is generated from the United States, followed by Sweden, China, EMEA (excluding Sweden), Japan, and other regions. This geographical diversity emphasizes Olink’s global impact and reach.

Olink has recently garnered attention through several strategic initiatives and developments. Notably, on March 20, 2024, Thermo Fisher Scientific received clearance from the Swedish Inspectorate of Strategic Products for a proposed transaction with Olink, expected to be completed by mid-2024. This collaboration is anticipated to further strengthen Olink's capabilities and market presence.

Investor Contacts:
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
Email: jan.medina@olink.com

Media Contacts:
Michael B. Gonzales, PhD
VP Global Marketing
Mobile: +1 415 308 6467
Email: michael.gonzales@olink.com

Rhea-AI Summary
Thermo Fisher Scientific reports Q3 2023 financial results, with revenue of $10.57 billion, a 1% decrease from the same quarter last year. GAAP diluted EPS was $4.42, a 17% increase YoY. The company also announced an agreement to acquire Olink Holding AB for $3.1 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Summary
Thermo Fisher to acquire Olink for $3.1 billion, enhancing capabilities in the proteomics market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
66.02%
Tags
-
Rhea-AI Summary
Olink Holding AB (Nasdaq: OLK) reports publication of three articles in Nature showcasing the power of the Olink Explore platform for proteogenomic studies. The studies used data from the UK Biobank Pharma Proteomics Project and demonstrated the value of proteogenomics in understanding biological mechanisms and accelerating drug development. The findings include over 14,000 genetic associations with protein expression levels, with 81% being novel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
Rhea-AI Summary
Olink Holding AB introduces Olink® Target 48 Mouse Cytokine Panel for translational research. The panel accurately measures 43 immune-related proteins using as little as 1µl of sample volume. It enables in-depth disease modeling and longitudinal studies. The panel's performance surpasses other platforms in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
none
-
Rhea-AI Summary
Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
none
-
Rhea-AI Summary
Olink Holding AB (OLK) to participate in investor events: Goldman Sachs 20th Annual European Medtech and Healthcare Services Conference on Sept 7th and Morgan Stanley 21st Annual Global Healthcare Conference on Sept 12th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.48%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.79%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none

FAQ

What is the current stock price of Olink Holding AB (publ) American Depositary Shares (OLK)?

The current stock price of Olink Holding AB (publ) American Depositary Shares (OLK) is $26.08 as of July 9, 2024.

What is the market cap of Olink Holding AB (publ) American Depositary Shares (OLK)?

The market cap of Olink Holding AB (publ) American Depositary Shares (OLK) is approximately 3.2B.

What does Olink Holding AB specialize in?

Olink Holding AB specializes in accelerating proteomics research through its proprietary Proximity Extension Assay (PEA) technology.

What are the main segments of Olink's operations?

Olink operates through two main segments: Kit, providing reagents for labs, and Services, offering data through Olink's labs.

Where is Olink Holding AB headquartered?

Olink Holding AB is headquartered in Uppsala, Sweden.

Which markets generate the most revenue for Olink?

The United States generates the most revenue for Olink, followed by Sweden, China, EMEA (excluding Sweden), Japan, and other regions.

What is Olink's Proximity Extension Assay (PEA) technology?

PEA is a patented technology that enables research across discovery, clinical trials, and diagnostic applications, using existing lab infrastructure.

Who are the key contacts for investors and media at Olink?

Investor contact: Jan Medina, CFA (jan.medina@olink.com). Media contact: Michael B. Gonzales, PhD (michael.gonzales@olink.com).

What recent strategic developments has Olink been involved in?

Olink has been involved in a proposed transaction with Thermo Fisher Scientific, expected to be completed by mid-2024.

When was Olink Holding AB founded?

Olink Holding AB was founded in 2016.

What industries benefit from Olink's services?

Biopharmaceutical companies, clinical institutions, and academic researchers benefit from Olink's proteomics services.

How can researchers use Olink's products?

Researchers can use Olink's products through the Kit segment in their labs or access services via Olink's own labs for high-quality data.

Olink Holding AB (publ) American Depositary Shares

NYSE:OLK

OLK Rankings

OLK Stock Data

3.24B
41.90M
66.41%
35.24%
2.03%
Diagnostics & Research
Healthcare
Link
United States of America
Uppsala